US pharma major Bristol Myers Squibb (NYSE: BMY) has decided to end its collaboration with Germany-based Immatics (Nasdaq: IMTX) for the co-development of IMA401.
The firm’s have been working together on the TCR-based bispecific cancer immunotherapy under the terms of a partnership established in late 2021.
The decision, driven by Bristol Myers' ongoing portfolio prioritization, will take effect on December 12, after which all rights to IMA401 will revert to Immatics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze